The historical rank and industry rank for Neumora Therapeutics's Equity-to-Asset or its related term are showing as below:
NMRA'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.43 Med: -0.71 Max: 0.95
Current: 0.94
During the past 5 years, the highest Equity to Asset Ratio of Neumora Therapeutics was 0.95. The lowest was -1.43. And the median was -0.71.
NMRA's Equity-to-Asset is ranked better than 93.15% of 1561
companies
in the Biotechnology industry
Industry Median: 0.67
vs NMRA: 0.94
Neumora Therapeutics Equity-to-Asset Historical Data
The historical data trend for Neumora Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Neumora Therapeutics's Equity-to-Asset
For the Biotechnology subindustry, Neumora Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neumora Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Neumora Therapeutics's Equity-to-Asset falls into.
Neumora Therapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Neumora Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Neumora Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Neumora Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Neumora Therapeutics (Neumora Therapeutics) Business Description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NMRA has been successfully added to your 